GlassScriptPhysician profile
Philip C Bird
NPI 1033187208
$9,027.60
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,344 · 2020: $438 · 2021: $1,413 · 2022: $1,740 · 2023: $2,690 · 2024: $1,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,093.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,659.12 | 2019-2024 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,138.65 | 2019-2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $856.74 | 2019-2024 | Trulance, Xifaxan |
| Gilead Sciences, INC. | $778.33 | 2019-2024 | Vemlidy, Epclusa |
| Janssen Biotech, INC. | $711.09 | 2019-2024 | Stelara, Simponi Aria, Simponi |
| Celgene Corporation | $409.53 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $268.11 | 2019-2024 | Ocaliva |
| Genzyme Corporation | $230.39 | 2023-2024 | |
| Cook Medical LLC | $222.96 | 2023 | Echotip, Hemospray |
| Pfizer INC. | $216.29 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $165.31 | 2022-2024 | Zeposia |
| Organon LLC | $151.41 | 2021-2023 | Hadlima, Renflexis |
| Qol Medical, LLC | $148.42 | 2019-2023 | Sucraid |
| Daiichi Sankyo INC. | $146.55 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $141.01 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $111.87 | 2019-2023 | Linzess |
| Romark Laboratories, Lc | $108.48 | 2019 | |
| Janssen Scientific Affairs, LLC | $106.34 | 2021 | |
| Ardelyx, INC. | $88.13 | 2022-2023 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $83.64 | 2021-2022 | |
| Olympus America INC. | $58.23 | 2019 | |
| Ucb, INC. | $46.67 | 2019 | |
| Sandoz INC. | $37.72 | 2023-2024 | Hyrimoz |
| Braintree Laboratories, INC. | $35.64 | 2019-2023 | Suflave |
| Redhill Biopharma INC. | $33.00 | 2020-2021 | |
| Lilly USA, LLC | $19.87 | 2023 | |
| Phathom Pharmaceuticals, INC. | $16.14 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $16.07 | 2023 | Dupixent |
| Endo Pharmaceuticals INC. | $10.96 | 2019 | |
| Allergan, INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Bird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.